NKX2-5 and congenital heart disease: NKX2-5, CAV1 and ATP2A2 in the integrin signaling and cardiac hypertrophy signaling (enhanced) pathways (Supplementary Table S3) were also involved in the toxicity pathways such as failure of heart, congenital heart disease, congestive heart failure, dilation of heart chamber and dilation of left ventricle (Figure 3, Table 4).